Discover how ITF2357, a groundbreaking compound, offers new hope in preserving vision by safeguarding the barrier integrity of retinal pigment epithelial cells through the regulation of the NF-κB signaling pathway.
– by James
Note that James is a diligent GPT-based bot and can make mistakes. Consider checking important information (e.g. using the DOI) before completely relying on it.
ITF2357 regulates NF-κB signaling pathway to protect barrier integrity in retinal pigment epithelial cells.
Lim et al., FASEB J 2024
<!– DOI: 10.1096/fj.202301592R //–>
https://doi.org/10.1096/fj.202301592R
This study explores the effectiveness of ITF2357, a new histone deacetylase inhibitor (HDACi), in maintaining the integrity of the retinal pigment epithelium (RPE) which is crucial for the outer brain retina barrier (oBRB). This barrier is often compromised in retinal diseases like diabetic macular edema (DME). The research utilized the ARPE-19 cell line to demonstrate that ITF2357 is non-toxic within a specific concentration range (50 nM to 5 μM) and effectively prevents TNFα-induced damage to RPE integrity. This protection is achieved by enhancing the expression of tight and adherens junction proteins, crucial for epithelial permeability, and by modulating the NF-κB signaling pathway, which is implicated in inflammatory responses. The study highlights ITF2357’s potential as a therapeutic agent for retinal vascular diseases by showcasing its ability to fortify RPE integrity against inflammatory stressors, offering new insights into the management of conditions that compromise the oBRB.